Fusion polypeptides capable of activating receptors
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsJames P. Fandl, Gang Chen, Nicholas J. Papadopoulos, Thomas H. Aldrich
Life of this patent
Estimating the term…
Abstract
A fusion polypeptide comprising (A)x-M-(A′)y, wherein A and A′ are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. A and A′ may be each be an antibody or fragment derived from an antibody specific for a target receptor, such as the same or different scFv fragments, and/or a ligand or ligand fragment or derivative capable of binding the target protein, M is a multimerizing component, and X and Y are independently a number between 1-10.
Claims20
A dimer formed from two fusion polypeptides of the form (A)-M-(A′), wherein components A and A′ are each a single chain variable fragment (scFv) antibody capable of binding Tie-1, and component M is a multimerizing component comprising an Fc domain of IgG, said dimer capable of binding to and clustering four or more Tie-1 receptors.
A fusion polypeptide comprising scFv2-1G3-Fc-scFv1-1F11 (SEQ ID NO:
- 51).
A fusion polypeptide comprising scFv1-1F11-Fc-scFv1-1F11 (SEQ ID NO:
- 50).
A dimer formed from two fusion polypeptides of the form (A)-M-(A′), wherein component A is a single chain variable fragment (scFv) antibody capable of binding Tie-1, component M is a multimerizing component comprising an Fc domain of IgG, and component A′ is a fibrinogen domain of Ang1 or Ang2, said dimer capable of binding to and clustering four or more Tie-1 receptors.
A fusion polypeptide comprising scFv1-1F11-Fc-FD1 (SEQ ID NO:
- 52).
A fusion polypeptide comprising scFv1-1F11-Fc-FD2 (SEQ ID NO:
- 53).
Dependencies are inferred from the claim text.